| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Impairment of other investments | 0 | 0 | - | - |
| Total other (loss) income, net | -1,593 | 4,456 | 5,172 | 5,922 |
| Net loss | -38,846 | -42,684 | -52,195 | -44,583 |
| Net unrealized gain (loss) on marketable securities | 144 | -101 | -133 | 1,157 |
| Comprehensive loss | -38,702 | -42,785 | -52,328 | -43,426 |
| Net loss per common share, basic (in dollars per share) | -2.13 | -2.89 | -0.18 | -0.17 |
| Net loss per common share, diluted (in dollars per share) | -2.13 | -2.89 | -0.18 | -0.17 |
| Weighted-average shares used to compute net loss per common share, basic (in shares) | 18,268,000 | 14,793,000 | 295,098,000 | 256,309,000 |
| Weighted-average shares used to compute net loss per common share, diluted (in shares) | 18,268,000 | 14,793,000 | 295,098,000 | 256,309,000 |
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)